RTW Investments-backed SPAV to acquire and merge with Immunovant in a $395m deal.

Health Sciences Acquisitions Corporation, a special purpose acquisition company sponsored by RTW Investments, agreed to acquire and merge with Immunovant, a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, in a $395m deal. "We are thrilled to have the opportunity to partner with the team at Immunovant. We believe IMVT-1401 is a uniquely compelling asset within the FcRn drug class, which we expect will become a cornerstone therapy for treating many auto-antibody driven diseases," Roderick T. Wong, M.D., President, Chief Executive Officer and Chairman of HSAC and Managing Partner and Chief Investment Officer of RTW Investments.